Clinical utility of complex mutations in the core promoter and proximal precore regions of the hepatitis B virus genome

Table 1 Hepatocellular carcinoma rate of specific mutation combinations and odds ratio in comparison with basal core promoter double mutation only

Specific mutation combinations	HCC1 rate	OR	95%CI	P-value
in combination with BCP2 double mutations
Wild-type	3.4% (1/29)	0.23	0.0048-2.0622	0.2391
BCP double mutations only [(A1762T + G1764A)]3	13.6% (6/44)	13
Dominant quadruple mutations
(G1613A + C1653T)	46.2% (6/13)	5.4286	5.4286-1.3530	0.0200
(C1653T + T1753V)	40.0% (2/5)	4.2222	4.2222-0.5797	0.1821
(C1653T + G1896A)	27.3% (6/20)	2.7143	2.7143-0.7495	0.1680
(T1753V + G1896A)	66.7% (14/21)	12.6667	12.6667-3.6262	0.0000
(A1846T + G1896A)	46.2% (6/13)	5.4286	5.4286-1.3530	0.0200
Dominant combinations in sextuplet mutations:
(G1613A + C1653T + A1846T + G1896A)	71.4% (5/7)	14.5142	1.8869-185.1359	0.0033
(G1613A + C1653T + A1846T + G1899A)	83.3% (5/6)	28.2555	2.5885-1517.9673	0.0012
Dominant combinations in septuplet mutations:
(G1613A + C1653T + T1753V + A1846T + G1896A)	100% (6/6)	Infinity	5.4236-infinity	0.0001
(G1613A + C1653T + A1846T + G1896A + G1899A)	85.7% (6/7)	39.3553	4.0487-2018.0433	0.0001

¹Hepatocellular carcinoma;

²Basal core promoter;

³Reference of odds ratio analyses; P-value was calculated by Fisher’s exact test for count data. BCP: Basal core promoter; HCC: Hepatocellular carcinoma.